Infinity Pharmaceuticals Inc. (NASDAQ:INFI) Director Michael C. Venuti sold 6,250 shares of the business’s stock in a transaction on Friday, March 17th. The stock was sold at an average price of $3.48, for a total transaction of $21,750.00. Following the sale, the director now directly owns 50,000 shares in the company, valued at approximately $174,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of Infinity Pharmaceuticals Inc. (NASDAQ:INFI) opened at 2.42 on Monday. The company has a 50 day moving average of $2.76 and a 200 day moving average of $1.77. Infinity Pharmaceuticals Inc. has a 52 week low of $0.84 and a 52 week high of $6.63. The company’s market cap is $122.03 million.
Infinity Pharmaceuticals (NASDAQ:INFI) last announced its quarterly earnings results on Tuesday, March 14th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.11. Infinity Pharmaceuticals had a net margin of 13.23% and a negative return on equity of 125.20%. The business’s revenue was down 100.0% compared to the same quarter last year. During the same period last year, the firm posted ($0.80) EPS. On average, analysts expect that Infinity Pharmaceuticals Inc. will post ($1.12) EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Michael C. Venuti Sells 6,250 Shares of Infinity Pharmaceuticals Inc. (INFI) Stock” was posted by BBNS and is owned by of BBNS. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://baseballnewssource.com/markets/infinity-pharmaceuticals-inc-infi-director-michael-c-venuti-sells-6250-shares-updated/518033.html.
A number of large investors have recently made changes to their positions in the company. Baker BROS. Advisors LP purchased a new stake in shares of Infinity Pharmaceuticals during the third quarter worth about $905,000. Numeric Investors LLC raised its stake in shares of Infinity Pharmaceuticals by 5.6% in the fourth quarter. Numeric Investors LLC now owns 779,899 shares of the company’s stock worth $1,053,000 after buying an additional 41,605 shares during the period. Oxford Asset Management raised its stake in shares of Infinity Pharmaceuticals by 63.5% in the fourth quarter. Oxford Asset Management now owns 343,172 shares of the company’s stock worth $463,000 after buying an additional 133,310 shares during the period. Teachers Advisors LLC raised its stake in shares of Infinity Pharmaceuticals by 39.4% in the fourth quarter. Teachers Advisors LLC now owns 105,961 shares of the company’s stock worth $143,000 after buying an additional 29,960 shares during the period. Finally, Tudor Investment Corp Et Al raised its stake in shares of Infinity Pharmaceuticals by 738.5% in the fourth quarter. Tudor Investment Corp Et Al now owns 165,998 shares of the company’s stock worth $224,000 after buying an additional 146,200 shares during the period. 79.56% of the stock is currently owned by institutional investors and hedge funds.
About Infinity Pharmaceuticals
Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.
Receive News & Ratings for Infinity Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.